Categories: News

Tauriga Sciences Inc. Announces Upcoming Commercial Launch of its Enhanced, 25mg CBD & CBG Infused, Version of Tauri-Gum

NEW YORK, NY, March 26, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced the upcoming commercial launch of its enhanced, 25mg Cannabidiol (“CBD”) & Cannabigerol (“CBG”) infused, version of Tauri-Gum™.  This 25mg product version will be available on E-Commerce (www.taurigum.com), on Stock Up Express (www.stockupexpress.com), in gas station convenience marts, in dispensaries, in supermarkets, in select medical practices, in a diverse setting of retail locations, and internationally.  The Company is highly confident in the future prospects of its flagship Tauri-Gum™ brand.   

The infusion concentrations of the following 5 Tauri-Gum™ SKUs have been increased to 25mg/each piece of chewing gum– – [3 SKUs] CBD Infused (Mint, Blood Orange, Pomegranate) / [2 SKUs] CBG Infused (Peach-Lemon, Black Currant).  

The Company has made the following strategic decision: There will be No Increase in Tauri-Gum™ Retail Prices (“MSRP”).  The Company has been successful in reducing costs (basic factors of production costs), pursuant to the Tauri-Gum™ manufacturing process.    

Lastly, the Company has been in multiple discussions and negotiations for potential Partnerships, both domestically and internationally.  The Company will update shareholders in a timely manner, should any material Agreement(s) be consummated.  

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

There can be no guarantees that any Partnership(s) or Agreement(s) will ultimately be consummated.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website:   www.tauriga.com

E-Commerce Website:  www.taurigum.com

Staff

Recent Posts

Optimind Pharma Closes First Tranche of Private Placement

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or…

13 mins ago

Element Science Receives Prestigious International Red Dot Design Award for Innovative Jewel® Patch Wearable Cardioverter Defibrillator

Novel technology recognized for its groundbreaking design and patient-centric innovationSAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative…

2 hours ago

StoryCorps Launches One Small Step America, a National Effort to Bridge Divides During a Contentious Election Year

One Small Step Pairs Strangers With Opposing Political Beliefs for One-on-One Conversations, Not to Debate…

5 hours ago

Navigate Announces Acquisition of Health Solutions, LLC

Positioning Navigate as a Leader in Comprehensive Wellbeing Solutions WEST DES MOINES, Iowa, July 8,…

5 hours ago

FDA Updates Guidance to Further Empower Companies to Address the Spread of Misinformation

SILVER SPRING, Md., July 8, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration…

5 hours ago

Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024

SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring…

5 hours ago